Physician profile
Mark Bauernfeind
NPI 1467870436
$2,914.08
in general payments reported to CMS, 2019-2025
10 companies · $54.26 in 2025
The $54.26 reported for 2025 was less than what a typical Physical Medicine & Rehabilitation provider received nationally (typical 2025 total: $138).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,256 · 2020: $75.21 · 2021: $50.93 · 2022: $69.84 · 2023: $545 · 2024: $863 · 2025: $54.26.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,057 · Travel and Lodging: $405.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,056.64 |
| Travel and Lodging | $405.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $1,836.59 | 2019-2025 | Intracept, Wavewriter Alpha Prime 16 |
| Medtronic, INC. | $338.32 | 2021-2023 | Intellis Adaptivestim |
| Relievant Medsystems, INC. | $195.29 | 2023 | Intracept |
| Nevro Corp. | $169.63 | 2019 | |
| Abbott Laboratories | $92.97 | 2019-2020 | |
| Hydrocision, INC. | $72.54 | 2021-2025 | Tenjet |
| Nalu Medical, INC. | $69.84 | 2022 | |
| Medtronic USA, INC. | $60.20 | 2019-2020 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $41.72 | 2019 | |
| Scilex Pharmaceuticals INC. | $23.95 | 2023 | Ztlido |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Bauernfeind listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.